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A rare case of isolated hepatic mucormycosis in association with
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Available online 15 October 2016AbstractRecent times have seen increasing frequencies of mucormycosis, especially in immunosuppressed individuals. This infection is associatedwith high
mortality. Clinicalmanifestations of the disease vary, but rhinoeorbitoecerebral and pulmonary involvements aremore common.Herewepresent a case
of a 32-year-old lady who was admitted with acute febrile illness with hemophagocytic syndrome. She was successfully treated but later developed an
isolated hepatic mucormycosis with a rapid fatal course. This case highlights the importance of a high index of clinical suspicion for fungal infections
especially in an immunosuppressed state. It emphasizes the need for aggressive and extensive work up to diagnose infections at unusual sites.
Copyright© 2016, Taiwan Society of EmergencyMedicine. Published byElsevier Taiwan LLC. This is an open access article under the CCBY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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1. Introduction fever associated with rigors, loss of appetite, and looseRecent times have seen an increasing rate of fungal in-
fections in both immunocompromised and immunocompetent
patients.1 Mucormycosis is a fatal opportunistic fungal infec-
tion usually seen in immunocompromised patients. It has
rhinocerebral, pulmonary, cutaneous, gastrointestinal, or
disseminated forms. Hepatic mucormycosis occurs as a part of
pulmonary or gastrointestinal involvement, and is considered a
component of disseminated mucormycosis.2 Isolated hepatic
mucormycosis is extremely rare and scarce literature exists
regarding the same. We describe a case of isolated hepatic
mucormycosis with a brief overview of this disease.2. Case Report
A 32-year-old woman presented to the emergency depart-
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The Medicity, 2nd Floor, Sector-38, Gurgaon, Haryana, 122001, India.
E-mail address: jobygeorge05@hotmail.com (J.V. George).
http://dx.doi.org/10.1016/j.jacme.2016.08.005
2211-5587/Copyright © 2016, Taiwan Society of Emergency Medicine. Published
ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).stools. She was a teetotaler, and usually had good health.
There was no history of rash, joint pains, cough, abdominal
discomfort, tick or fleabite or animal exposure, recent travel,
use of supplements, illicit drugs, or unpasteurized milk. She
was residing in Nepal where she was found to have deranged
liver function tests with bilateral pleural effusions and peri-
cardial effusion. She tested brucella antibody positive for
which doxycycline and streptomycin were started to which she
did not respond. On arrival to intensive care, we found an
average built, conscious, hemodynamicaly stable, pale woman
with a temperature of 38.5C. Cardiac and respiratory exam-
inations were unremarkable except for tachypnoea and biba-
silar decreased breath sounds. The rest of the systemic
examination showed hepatomegaly. She was empirically
started on artesunate as she hailed from an area endemic for
malaria, along with doxycycline and streptomycin. In-
vestigations at admission showed the following values:
hemoglogin 8.8 g/dL, white cell count of 5.8  103/mL (neu-
trophils 75.2%, lymphocytes 18.9%, eosinophils 0.0%, and
monocytes 5.9%), platelet counts 159  103/mL, urea 31 mg/
dL, creatinine 0.8 mg/dL, bilirubin 5.6mg/dL, aspartate
transaminase/alanine aminotransferase of 750/1557 U/L, andby Elsevier Taiwan LLC. This is an open access article under the CC BY-NC-
Table 1
Laboratory investigations.
Aspartate transaminase: 1557 U/L Serum triglycerides: 349 mg/dL
Haptoglobin: 14 mg/dL Lactate dehydrogenase: 37,000 U/L
Fibrinogen: 58.5 mg/dL Ceruloplasmin: 24.4 mg/dL
Ferritin: 14,037 ng/mL D-dimer > 20
Serum procalcitonin: 4.88 ng/mL Galactomannan antigen: negative
Blood culture: sterile Antinuclear antibody: negative
Blood culture: fungal negative
Coomb's test indirect: negative Coomb's test direct: negative
Bone marrow aspiration Maturation arrest with
hemophagocytosis
Bone marrow examination No Leishman-Donovan bodies
Bone marrow culture Sterile
Pleural fluid analysis
Protein: 3.8 g/dL Glucose: 110 mg/dL
Total leucocyte count: 40 cells/uL
N e 70 % L e 30%
Lactate dehydrogenase: 1883 IU
Adenosine deaminase: 11 IU/L
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226 mg/dL. She was negative for malaria, leptospira, dengue,
Hepatitis A, B, C, E, and V, and brucellosis. She was detected
to be typhidot immunoglobulin-M positive, so intravenous
ceftriaxone and amikacin were started in addition to doxycy-
cline and the rest were discontinued. A computed tomography
scan of the chest and abdomen showed bilateral pleural effu-
sions, mild pericardial effusion, hepatomegaly, and choleli-
thiasis. Transthoracic echocardiography showed normal left
ventricular function with minimal pericardial effusion. Blood
and urine cultures did not show any growth.
Over the next few days she developed pancytopenia (he-
moglobin 5.5 g/dL, white cell count 2.35  103/mL (neutro-
phils 45.7%, lymphocytes 22.3%, eosinophils 0.0%, and
monocytes 32%), platelets 55  103/mL, and further wors-
ening of liver function tests. She also needed ventilatory
support for worsening respiratory failure. On further work-up
she was found to be negative for Epstein-Barr virus, cyto-
megalovirus, and parvovirus. She was found to have raised
levels of ferritin, lactate dehydrogenase, and triglycerides.Figure 1. (A) Computed tomography of the abdomen showing hypodense lesions in
at right angles typical of Mucor species.Pleural fluid analysis showed exudative lymphocytic effusion.
As there was a possibility of hemophagocytosis syndrome, a
bone marrow aspiration was performed (Table 1).
A diagnosis of secondary hemophagocytic syndrome (HPS)
was made possibly due to either enteric fever or brucellosis.
Intravenous immunoglobulins, valaciclovir, and vor-
iconazole were started. The patient improved clinically over a
few days. Ventilatory support and vasopressors were dis-
continued. She was shifted out of intensive care after 10 days.
Antibiotics and prophylactic voriconazole were continued.
However, a week later she developed fever along with right
hypochondriac tenderness. The Ear, Nose, and Throat team
reported normal nasal passages, nasal septum, posterior
pharyngeal wall congestion, and normal uvula. Repeat contrast
enhanced computed tomography of the head, neck, chest, and
abdomen showed right pleural effusion and two space occu-
pying lesions in the subdiaphragmatic part of the liver with
right hepatic vein thrombosis (Figure 1A).
Pleural fluid was exudative, lymphocytic with normal
adenosine deaminase levels, and no growth on pyogenic,
fungal, and mycobacterial cultures.
Amoebic serology was negative. Trucut biopsy of the liver
mass revealed invasive mucormycosis (Figure 1B). The patient
was started on amphotericin B and posaconazole and under-
went surgical excision of lesions. Unfortunately, she suc-
cumbed to her illness few days later.
3. Discussion
Mucormycosis is an emerging opportunistic fungal infec-
tion caused by fungi of subphylum mucormycotia.3 We are
witnessing a recent increase in this infection due to multiple
reasons. Firstly, there is an increase in immunocompromised
patients with better medical care and improved diagnostics.
Secondly, with effective management of infections caused by
candida and aspergillus with newer antifungal agents, less
common opportunistic agents are becoming prominent.4 In
India the incidence has risen from 13 cases annually in
1990e1999 to 50 cases annually in 2006e2007.5,6the liver; (B) liver biopsy showing rectangular-shaped aseptate hyphae arising
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dividuals. It also occurs in association with iron overload,
desferoxamine therapy, and use of voriconazole or
caspofungin.3,7e10 In developed countries it occurs usually in
transplant recipients and neutropenia.11,12 In India it has been
found to be more common in diabetic patients.13,14
In immunocompetent patients, mucormycosis usually oc-
curs after traumatic inoculation, and commonly manifests as
primary cutaneous and rhinoeorbitalecerebral diseases.
There have been reports of isolated renal mucormycosis in the
immunocompetent population from India. Mucormycosis
outbreaks, defined as more than two cases in 3e6 months, are
extremely uncommon.13 The infection has a relentless fatal
course in the absence of prompt diagnosis and early therapy.
It is acquired via sinuses, lungs, gastrointestinal tract, or
skin inoculation. It manifests as rhinocerebral, pulmonary,
cutaneous (especially in burn patients), gastrointestinal, and
disseminated forms.1,2 Rhinocerebral and pulmonary systems
are more frequently involved. Disseminated mucormycosis
represents the most severe and life threatening form. An ante-
mortem diagnosis is made in only less than 10% of patients.15
The hallmark of mucormycosis is vascular invasion by hyphae
leading to thrombosis and tissue necrosis. Dissemination
presumably occurs via the bloodstream. Hepatic involvement
is very rare.1,2 Hepatic mucormycosis has been associated
with diabetes, chemotherapy, bone marrow transplantation,
and solid organ transplants.
To the best of our knowledge this is the first report of
occurrence of hepatic mucormycosis in HPS. Risk factors in
our patient were HPS, a relatively immune deficient state, and
use of voriconazole. The source may have been gastrointes-
tinal. A pulmonary source of infection was not evident
radiologically as well as microbiologically.
Mucormycosis in voriconazole recipients, a risk factor in
this case, has been reported previously.16e19 In patients who
are receiving voriconazole, either prophylactically or thera-
peutically or both, breakthrough mucormycosis occurs in
0e8.9%, 0.5%, and 4.3% of patients, respectively.18e22
Changes in host immunosuppression status due to wide-
spread voriconazole use and increase in virulence after vor-
iconazole exposure are presumed to be responsible.23,24
A high index of clinical suspicion is critical for survival.
Investigations including blood or sputum culture, bron-
choalveolar lavage, computed tomography scan, or magnetic
resonance imaging aid in narrowing the differential diagnosis
but have a low specificity.
Hepatic mucormycosis is seen as a hypodense lesion sur-
rounding the vessels without any mass effect on computed
tomography imaging. These findings usually indicate
angioinvasive pathology. Tissue culture and pathologic ex-
amination provide the only means of a definite diagnosis.
Tissue examination shows large, ribbon-like or irregularly-
shaped, broad hyphae with occasional septae, with right
angle branching characteristic of mucorales. Perivascular and
blood vessel invasion resulting in arterial thrombosis with
necrosis is pathognomonic.1,25 Recently quantitative poly-
merase chain reaction has shown to be valuable in diagnosis.Prompt diagnosis and a combined medicalesurgical
approach are necessary for successful treatment.3,7,26,27 Med-
ical measures include early initiation of appropriate antifungal
therapy, and rapid control of risk factors. Surgical debridement
of nonviable tissue, when applicable, is mandatory. Prolonged
high dose of amphotericin B or liposomal amphotericin B,
reaching doses of 1 mg/kg/d and 5e10 mg/kg/d, respectively,
is the recommended antifungal therapy.27 A delay in ampho-
tericin B initiation (> 6 days after diagnosis) has been shown
to double the mortality rate.28 Recently posaconazole, a tri-
azole, has been reported to be beneficial for prophylaxis in
immunocompromised hosts. It has been used as a salvage
therapy in patients who either failed or did not tolerate
amphotericin B. It is, however, not recommended as the pri-
mary first line therapy.29 Echinocandins were found to have a
synergistic effect with amphotericin B in various studies.
There have been suggestions that amphotericin B and echi-
nocandins should be used in combination for the first 3 weeks
of therapy, with transition to oral posaconazole subsequently
for maintenance.
Tacrolimus and sirolimus also seem to be protective against
mucormycosis.30 Less known therapeutic agents include iron-
chelating agents, colistin, statins, granulocyteemacrophage
colony-stimulating factor, interferon-g, and hyperbaric
oxygen.4
In conclusion, this report highlights the broad clinical
spectrum of mucormycosis. The key components of successful
management are a high index of suspicion, early diagnosis,
prompt appropriate antifungal therapy, with timely surgical
intervention.Conflicts of interest
The authors declare that they have no conflicts of interest.
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